Patents matching “formulation”

US 9114146

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Aug 25, 2015 · Expires Aug 20, 2035

US 9089506

Stable, non-irritating topical formulations of hydroquinone

Precision Dermatology, Inc. · Granted Jul 28, 2015 · Expires Jul 23, 2035

US 9072710

Injectable ibuprofen formulation

Cumberland Pharmaceuticals Inc. · Granted Jul 7, 2015 · Expires Jul 2, 2035

US 9072661

Injectable ibuprofen formulation

Cumberland Pharmaceuticals Inc. · Granted Jul 7, 2015 · Expires Jul 2, 2035

US 9060941

Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

Takeda Pharmaceutical Company Limited · Granted Jun 23, 2015 · Expires Jun 18, 2035

US 9044498

Lyophilized viral formulations

ONCOLYTICS BIOTECH INC. · Granted Jun 2, 2015 · Expires May 28, 2035

US 9045728

Liquid viral formulations

ONCOLYTICS BIOTECH INC. · Granted Jun 2, 2015 · Expires May 28, 2035

US 9040061

Topical formulation for administering a compound

Rigel Pharmaceuticals, Inc. · Granted May 26, 2015 · Expires May 21, 2035

US 9023356

Treatment method using EGFR antibodies and SRC inhibitors and related formulations

The Regents of the University of California · Granted May 5, 2015 · Expires Apr 30, 2035

US 9018170

Reduced volume formulation of glatiramer acetate and methods of administration

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 28, 2015 · Expires Apr 23, 2035

US 9012434

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Apr 21, 2015 · Expires Apr 16, 2035

US 9006222

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Apr 14, 2015 · Expires Apr 9, 2035

US 8993548

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Mar 31, 2015 · Expires Mar 26, 2035

US 8993519

Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 31, 2015 · Expires Mar 26, 2035

US 8993549

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Mar 31, 2015 · Expires Mar 26, 2035

US 8992989

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Mar 31, 2015 · Expires Mar 26, 2035

US 8986653

Labeled iodinated tropane formulation

Alseres Pharmaceuticals, Inc. · Granted Mar 24, 2015 · Expires Mar 19, 2035

US 8987238

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Mar 24, 2015 · Expires Mar 19, 2035

US 8987237

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Mar 24, 2015 · Expires Mar 19, 2035

US 8962038

Nitrite formulations and their use as nitric oxide prodrugs

The Board of Regents of the University of Texas System · Granted Feb 24, 2015 · Expires Feb 19, 2035

US 8951504

(trimethoxyphenylamino) pyrimidinyl formulations

Rigel Pharmaceuticals, Inc. · Granted Feb 10, 2015 · Expires Feb 5, 2035

US 8945559

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Feb 3, 2015 · Expires Jan 29, 2035

US 8945635

Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers

Southern Connecticut State University · Granted Feb 3, 2015 · Expires Jan 29, 2035

US 8933115

Stabilized statin formulations

Cumberland Pharmaceuticals Inc. · Granted Jan 13, 2015 · Expires Jan 8, 2035